Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10618987 | 0.81 | TSHR (0.39) | — | |
| SCHEMBL4013578 | 0.78 | GAA (0.43) | — | |
| SCHEMBL4312348 | 0.76 | LMNA (0.36) | CYP2D6 | |
| SCHEMBL2725240 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL8216952 | 0.76 | — | — | |
| SCHEMBL15063824 | 0.76 | DGAT1 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL6351731 | 0.75 | TDP1 (0.42) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL4784310 | 0.74 | CYP2D6 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL64420 | 0.74 | CYP2D6 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL3363552 | 0.74 | CYP2D6 (0.33) | CYP2D6DGAT1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | claimed |
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | Nexoligo Co., Ltd. (KR) | 2023-07-27 | — | — | US | claimed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | claimed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | claimed |
| US-20230102721-A1 | NOVEL ORGANIC ELECTRON TRANSFER MEDIATOR AND DEVICE COMPRISING SAME | I-SENS, INC. (KR) | 2023-03-30 | — | — | US | claimed |
| EP-4083043-A1 | NOVEL ORGANIC ELECTRON TRANSFER MEDIATOR AND DEVICE COMPRISING SAME | I-SENS, INC. (KR) | 2022-11-02 | — | — | EP | claimed |
| EP-4079732-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | claimed |
| EP-3359580-B1 | POLYMER HAVING ANTIMICROBIAL AND/OR ANTIFOULING PROPERTIES | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2022-03-30 | — | — | EP | claimed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | claimed |
| EP-0421682-B1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO LTD (JP) | 1997-03-26 | — | — | EP | claimed |
| US-5565574-A | BIOSYNTHESIS OF SYNTHETIC PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-10-15 | — | — | US | claimed |
| EP-0703900-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE DERIVATIVES OR HOMOLOGUES CONTAINING A GUANIDINO OR MODIFIED GUANIDINO GROUP USEFUL FOR THE PREPARATION GnRH OF ANTAGONISTIC PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-04-03 | — | — | EP | claimed |
| US-5420277-A | BACTERICIDE INTERMEDIATES | E. R. SQUIBB & SONS, INC. (US) | 1995-05-30 | — | — | US | claimed |
| EP-0540626-A1 | PROCESS FOR SYNTHESIZING PEPTIDES | EASTMAN CHEMICAL COMPANY (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0538692-A1 | Use of partly known substituted pyrrolidine derivatives as pharmaceuticals, new compounds and process for their preparation | BAYER AG (DE) | 1993-04-28 | — | — | EP | claimed |
| EP-0132770-B1 | INSULIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-16 | — | — | EP | claimed |
| EP-0137361-A2 | Insulin derivatives modified in position B 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-17 | — | — | EP | claimed |
| EP-0132770-A1 | Insulin derivatives, processes for their preparation, their use and pharmaceutical compositions for the treatment of diabetes mellitus | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-02-13 | — | — | EP | claimed |
| US-4400377-A | Use of polypeptides as analgesic drugs | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1983-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | RNGTT, MPO, RNMT | CYP2D6 4024/4885DGAT1 2280/4885HDAC3 3109/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CYP2D6 2923/4885DGAT1 1432/4885HDAC3 4149/4885 |
| US-20230102721-A1 | NOVEL ORGANIC ELECTRON TRANSFER MEDIATOR AND DEVICE COMPRISING SAME | MT-ND4, MT-ND2, SLC25A21 | CYP2D6 1896/4885DGAT1 388/4885HDAC3 4780/4885 |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | CYP2D6 1940/4885DGAT1 1871/4885HDAC3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.